{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:06:06Z","timestamp":1789506366799,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000190","name":"US Department of Commerce","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118580","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:58:43Z","timestamp":1768319923000},"page":"118580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Small-molecule modulators of the androgen receptor N-terminal domain: Advances in medicinal chemistry for prostate cancer"],"prefix":"10.1016","volume":"305","author":[{"given":"Inderpal","family":"Sekhon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Ashong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-1824","authenticated-orcid":false,"given":"Qiao-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118580_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118580_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.118580_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4103\/1008-682X.181081","article-title":"A sting in the tail: the N-terminal domain of the androgen receptor as a drug target","volume":"18","author":"Monaghan","year":"2016","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.ejmech.2026.118580_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/biomedicines8100422","article-title":"The androgen receptor in prostate cancer: effect of structure, ligands and spliced variants on therapy","volume":"8","author":"Messner","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118580_bib5","doi-asserted-by":"crossref","first-page":"30910","DOI":"10.1074\/jbc.M705524200","article-title":"Structure characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12","volume":"282","author":"Cantin","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118580_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118580_bib8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118580_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"ARAMIS investigators, Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118580_bib10","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1007\/s00018-011-0766-7","article-title":"Androgen receptor and its splice variants in prostate cancer","volume":"68","author":"Haile","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2026.118580_bib11","article-title":"Computational analysis of androgen receptor (AR) variants to decipher the relationship between protein stability and related-diseases","volume":"10","author":"Chen","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118580_bib12","article-title":"N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118580_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1039\/C1MB05249G","article-title":"Intrinsic disorder in the androgen receptor: identification, characterisation and drugability","volume":"8","author":"McEwan","year":"2012","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ejmech.2026.118580_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/1097-0134(20001115)41:3<415::AID-PROT130>3.0.CO;2-7","article-title":"Why are \"natively unfolded\" proteins unstructured under physiologic conditions?","volume":"41","author":"Uversky","year":"2000","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2026.118580_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrm3920","article-title":"Intrinsically disordered proteins in cellular signaling and regulation","volume":"16","author":"Wright","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12964-022-00821-7","article-title":"Intrinsically disordered proteins play diverse roles in cell signaling","volume":"20","author":"Bondos","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2026.118580_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214050","article-title":"Intrinsically disordered proteins: an overview","volume":"23","author":"Trivedi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118580_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fmolb.2014.00006","article-title":"Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators","volume":"1","author":"Uversky","year":"2014","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2026.118580_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrm.2017.7","article-title":"Biomolecular condensates: organizers of cellular biochemistry","volume":"18","author":"Banani","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib20","doi-asserted-by":"crossref","first-page":"9729","DOI":"10.1021\/acsomega.2c07708","article-title":"Fuzzy drug targets: disordered proteins in the drug-discovery realm","volume":"8","author":"Saurabh","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118580_bib21","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.jmb.2018.04.008","article-title":"Targeting intrinsically disordered transcription factors: changing the paradigm","volume":"430","author":"Tsafou","year":"2018","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cbpa.2021.02.009","article-title":"Intrinsically disordered proteins and biomolecular condensates as drug targets","volume":"62","author":"Biesaga","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib23","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1634\/theoncologist.2016-0161","article-title":"Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer","volume":"21","author":"Antonarakis","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.118580_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115077","article-title":"Targeting the N-terminal domain of the androgen receptor: the effective approach in therapy of CRPC","volume":"247","author":"Ji","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118580_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4334","article-title":"Topological dynamics of an intrinsically disordered N-terminal domain of the human androgen receptor","volume":"31","author":"Sheikhhassani","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2026.118580_bib27","first-page":"2499","article-title":"EPI-001, A compound active against castration-resistant prostate cancer, targets transactivation unit 5 of the androgen receptor, ACS Chem","volume":"11","author":"de Mol","year":"2016","journal-title":"Biol"},{"key":"10.1016\/j.ejmech.2026.118580_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/pro.5254","article-title":"Ion mobility mass spectrometry unveils conformational effects of drug lead EPI-001 on the intrinsically disordered N-terminal domain of the androgen receptor","volume":"34","author":"Ahmed","year":"2025","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2026.118580_bib29","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1172\/JCI66398","article-title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.118580_bib30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10637-021-01202-6","article-title":"A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer","volume":"40","author":"Maurice-Dror","year":"2022","journal-title":"Invest. New Drugs"},{"issue":"7_suppl","key":"10.1016\/j.ejmech.2026.118580_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.2019.37.7_suppl.257","article-title":"Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor","volume":"37","author":"Le Moigne","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118580_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/acsptsci.9b00065","article-title":"Revealing metabolic liabilities of ralaniten to enhance novel androgen receptor targeted therapies","volume":"2","author":"Obst","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.118580_bib33","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1878-0261.12770","article-title":"Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer","volume":"14","author":"Hirayama","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118580_bib34","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1038\/s41467-022-34077-z","article-title":"Small molecules targeting the disordered transactivation domain of the androgen receptor induce the formation of collapsed helical states","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"issue":"Supplement 5","key":"10.1016\/j.ejmech.2026.118580_bib35","doi-asserted-by":"crossref","first-page":"v189","DOI":"10.1093\/annonc\/mdz244.065","article-title":"EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","volume":"30","author":"Le Moigne","year":"2019","journal-title":"Ann. Oncol."},{"issue":"Number 6_suppl","key":"10.1016\/j.ejmech.2026.118580_bib36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2020.38.6_suppl.142","article-title":"IND Candidate EPI-7386 as an N-terminal domain androgen receptor Inhibitor in development for the treatment of prostate cancer","volume":"38","author":"Le Moigne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118580_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2023.41.6_suppl.179","article-title":"Phase 1\/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Laccetti","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118580_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87850","article-title":"An imaging agent to detect androgen receptor and its active splice variants in prostate cancer","volume":"1","author":"Imamura","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2026.118580_bib39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41589-022-01151-y","article-title":"Targeting androgen receptor phase separation to overcome antiandrogen resistance","volume":"18","author":"Xie","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1021\/acsmedchemlett.6b00186","article-title":"Small molecule antagonists of the nuclear androgen receptor for the treatment of castration-resistant prostate cancer","volume":"7","author":"Johnson","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118580_bib41","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1210\/en.2017-00408","article-title":"Inhibition of androgen receptor function and level in castration-resistant prostate cancer cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone","volume":"158","author":"Masoodi","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2026.118580_bib42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1535-7163.MCT-19-0489","article-title":"A novel small molecule targets androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"19","author":"Yang","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2026.118580_bib43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/1535-7163.MCT-21-0432","article-title":"(+)-JJ-74-138 is a novel noncompetitive androgen receptor antagonist","volume":"21","author":"Cole","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2026.118580_bib44","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/ol802021w","article-title":"Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells","volume":"10","author":"Sadar","year":"2008","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2026.118580_bib45","doi-asserted-by":"crossref","first-page":"22231","DOI":"10.1074\/jbc.M116.734475","article-title":"Sintokamide A is a novel antagonist of androgen receptor that uniquely binds activation function-1 in its amino-terminal domain","volume":"291","author":"Banuelos","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acs.jnatprod.0c00921","article-title":"Structure-activity relationships for the marine natural product sintokamides: androgen receptor N-terminus antagonists of interest for treatment of metastatic castration-resistant prostate cancer","volume":"84","author":"Yan","year":"2021","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2026.118580_bib47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10565-020-09511-x","article-title":"Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain","volume":"36","author":"Peng","year":"2020","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118580_bib48","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s42003-021-02321-9","article-title":"Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage","volume":"4","author":"Gjyrezi","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/adt.2021.128","article-title":"Development of a high-throughput screening assay for small-molecule inhibitors of androgen receptor splice variants","volume":"20","author":"Monaghan","year":"2022","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejmech.2026.118580_bib50","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1021\/acsmedchemlett.3c00426","article-title":"Synthesis and evaluation of small molecule inhibitors of the androgen receptor N-terminal domain","volume":"14","author":"Henry","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118580_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211832120","article-title":"Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer","volume":"120","author":"Thiyagarajan","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejmech.2026.118580_bib52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/protein\/gzx058","article-title":"Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy","volume":"30","author":"Goicochea","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ejmech.2026.118580_bib53","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"suppl 15","key":"10.1016\/j.ejmech.2026.118580_bib54","doi-asserted-by":"crossref","first-page":"642a","DOI":"10.1158\/1538-7445.AM2015-642","article-title":"Cell-penetrating bispecific antibodies for targeting androgen receptor signaling in advanced prostate cancer","volume":"75","author":"Goicochea","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118580_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0304-3835(03)00151-4","article-title":"Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells","volume":"195","author":"Weisbart","year":"2003","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118580_bib56","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1158\/1535-7163.MCT-22-0237","article-title":"Discovery of a small-molecule inhibitor targeting the androgen receptor N-terminal domain for castration-resistant prostate cancer","volume":"22","author":"Yi","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2026.118580_bib57","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41388-024-02944-2","article-title":"SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain","volume":"43","author":"Yi","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118580_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104500","article-title":"Targeting androgen receptor and the variants by an orally bioavailable proteolysis targeting Chimeras compound in castration resistant prostate cancer","volume":"90","author":"Hung","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2026.118580_bib59","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1021\/acs.jmedchem.2c01487","article-title":"A comprehensive overview of small-molecule androgen receptor degraders: recent progress and future perspectives","volume":"65","author":"Ha","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib60","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","article-title":"Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting N-terminal domain for the treatment of prostate cancer","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117079","article-title":"Discovery of a highly potent, N-terminal domain-targeting degrader of AR-FL\/AR-V7 for the treatment of prostate cancer","volume":"282","author":"Ha","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"Suppl. S1","key":"10.1016\/j.ejmech.2026.118580_bib62","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0959-8049(22)00898-X","article-title":"Advances in the development of a targeted N-terminal domain androgen receptor (AR) degrader (ANITAC) for the treatment of prostate cancer","volume":"174","author":"Hong","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118580_bib63","article-title":"Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer","volume":"71","author":"Hung","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2026.118580_bib64","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1021\/acs.jmedchem.3c02177","article-title":"Structure-activity relationship (SAR) studies of novel monovalent AR\/AR-V7 dual degraders with potent efficacy against advanced prostate cancer","volume":"67","author":"Xiao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118259","article-title":"Development of dual AR\/ARV7 degraders with 3,5-dimethylisoxazole to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"301","author":"Zhang","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib66","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70700","article-title":"Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"12","author":"Wu","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118580_bib67","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118580_bib68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acs.jmedchem.8b00973","article-title":"New generation of selective androgen receptor degraders: our initial design, synthesis, and biological evaluation of new compounds with enzalutamide-resistant prostate cancer activity","volume":"62","author":"Hwang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib69","doi-asserted-by":"crossref","first-page":"12642","DOI":"10.1021\/acs.jmedchem.0c00943","article-title":"Pyrazol-1-yl-propanamides as SARD and pan-antagonists for the treatment of enzalutamide-resistant prostate cancer","volume":"63","author":"He","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib70","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1021\/acs.jmedchem.1c00439","article-title":"Exploration and biological evaluation of basic heteromonocyclic propenamide derivatives as SARDs for the treatment of enzalutamide-resistant prostate cancer","volume":"64","author":"He","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118580_bib71","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-17-0976","article-title":"Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer","volume":"77","author":"Ponnusamy","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118580_bib72","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/acschembio.1c00390","article-title":"Development of a benzothiazole scaffold-based androgen receptor N-terminal inhibitor for treating androgen-responsive prostate cancer","volume":"16","author":"Kuznik","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib73","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.chembiol.2020.10.001","article-title":"Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors","volume":"28","author":"Richters","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118580_bib74","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118580_bib75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/nar\/gkac1158","article-title":"Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.118580_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3958","article-title":"Coactivator condensation at super-enhancers links phase separation and gene control","volume":"361","author":"Sabari","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118580_bib77","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118580_bib78","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1080\/07391102.2024.2333454","article-title":"In silico study of androgen receptor N-terminal domain and exploration of its modulators","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Biomol. Struct. Dyn."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:48:19Z","timestamp":1773978499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":78,"alternative-id":["S0223523426000255"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118580","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small-molecule modulators of the androgen receptor N-terminal domain: Advances in medicinal chemistry for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118580"}}